160 related articles for article (PubMed ID: 29254882)
21. Validation of a treadmill six-minute walk test protocol for the evaluation of patients with pulmonary arterial hypertension.
Camargo VM; Martins Bdo C; Jardim C; Fernandes CJ; Hovnanian A; Souza R
J Bras Pneumol; 2009 May; 35(5):423-30. PubMed ID: 19547850
[TBL] [Abstract][Full Text] [Related]
22. Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension.
Simonneau G; Rubin LJ; Galiè N; Barst RJ; Fleming TR; Frost A; Engel P; Kramer MR; Serdarevic-Pehar M; Layton GR; Sitbon O; Badesch DB;
J Heart Lung Transplant; 2014 Jul; 33(7):689-97. PubMed ID: 24815795
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial.
Jing ZC; Parikh K; Pulido T; Jerjes-Sanchez C; White RJ; Allen R; Torbicki A; Xu KF; Yehle D; Laliberte K; Arneson C; Rubin LJ
Circulation; 2013 Feb; 127(5):624-33. PubMed ID: 23307827
[TBL] [Abstract][Full Text] [Related]
24. Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial.
Souza R; Channick RN; Delcroix M; Galiè N; Ghofrani HA; Jansa P; Le Brun FO; Mehta S; Perchenet L; Pulido T; Sastry BKS; Sitbon O; Torbicki A; Rubin LJ; Simonneau G
PLoS One; 2018; 13(3):e0193226. PubMed ID: 29590122
[TBL] [Abstract][Full Text] [Related]
25. Bosentan therapy in patients with pulmonary arterial hypertension: the relationship between improvements in 6 minute walk distance and quality of life.
Strange G; Keogh AM; Williams TJ; Wlodarczyk J; McNeil KD; Gabbay E
Respirology; 2008 Sep; 13(5):674-82. PubMed ID: 18713089
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials.
Liu HL; Chen XY; Li JR; Su SW; Ding T; Shi CX; Jiang YF; Zhu ZN
Chest; 2016 Aug; 150(2):353-66. PubMed ID: 27048870
[TBL] [Abstract][Full Text] [Related]
27. Creation of a model comparing 6-minute walk test to metabolic equivalent in evaluating treatment effects in pulmonary arterial hypertension.
Gomberg-Maitland M; Huo D; Benza RL; McLaughlin VV; Tapson VF; Barst RJ
J Heart Lung Transplant; 2007 Jul; 26(7):732-8. PubMed ID: 17613405
[TBL] [Abstract][Full Text] [Related]
28. Factors associated with the 6-minute walk distance in patients with systemic sclerosis.
Sanges S; Giovannelli J; Sobanski V; Morell-Dubois S; Maillard H; Lambert M; Podevin C; Lamblin N; De Groote P; Bervar JF; Perez T; Matran R; Rémy-Jardin M; Hatron PY; Hachulla É; Launay D
Arthritis Res Ther; 2017 Dec; 19(1):279. PubMed ID: 29246248
[TBL] [Abstract][Full Text] [Related]
29. Utility of right ventricular Tei-index for assessing disease severity and determining response to treatment in patients with pulmonary arterial hypertension.
Ogihara Y; Yamada N; Dohi K; Matsuda A; Tsuji A; Ota S; Ishikura K; Nakamura M; Ito M
J Cardiol; 2014 Feb; 63(2):149-53. PubMed ID: 24012334
[TBL] [Abstract][Full Text] [Related]
30. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N
Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
[TBL] [Abstract][Full Text] [Related]
31. No Placebo Effect beyond Regression to the Mean on the Six Minute Walk Test in Pulmonary Arterial Hypertension Trials.
Anheyer D; Bugaj TJ; Lüdtke R; Appelbaum S; Trübel H; Ostermann T
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674584
[TBL] [Abstract][Full Text] [Related]
32. Minimal Clinically Important Difference in the 6-minute-walk Distance for Patients with Pulmonary Arterial Hypertension.
Moutchia J; McClelland RL; Al-Naamani N; Appleby DH; Blank K; Grinnan D; Holmes JH; Mathai SC; Minhas J; Ventetuolo CE; Zamanian RT; Kawut SM
Am J Respir Crit Care Med; 2023 Apr; 207(8):1070-1079. PubMed ID: 36629737
[No Abstract] [Full Text] [Related]
33. Evidence-based pharmacologic management of pulmonary arterial hypertension.
Benedict N; Seybert A; Mathier MA
Clin Ther; 2007 Oct; 29(10):2134-53. PubMed ID: 18042471
[TBL] [Abstract][Full Text] [Related]
34. BMI and Treatment Response in Patients With Pulmonary Arterial Hypertension: A Meta-analysis.
McCarthy BE; McClelland RL; Appleby DH; Moutchia JS; Minhas JK; Min J; Mazurek JA; Smith KA; Fritz JS; Pugliese SC; Urbanowicz RJ; Holmes JH; Palevsky HI; Kawut SM; Al-Naamani N
Chest; 2022 Aug; 162(2):436-447. PubMed ID: 35247393
[TBL] [Abstract][Full Text] [Related]
35. Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial.
Fischer A; Denton CP; Matucci-Cerinic M; Gillies H; Blair C; Tislow J; Nathan SD
Respir Med; 2016 Aug; 117():254-63. PubMed ID: 27492539
[TBL] [Abstract][Full Text] [Related]
36. Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT.
Kawut SM; Bagiella E; Lederer DJ; Shimbo D; Horn EM; Roberts KE; Hill NS; Barr RG; Rosenzweig EB; Post W; Tracy RP; Palevsky HI; Hassoun PM; Girgis RE;
Circulation; 2011 Jun; 123(25):2985-93. PubMed ID: 21593252
[TBL] [Abstract][Full Text] [Related]
37. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study.
Huo Y; Jing ZC; Zeng XF; Liu JM; Yu ZX; Zhang GC; Li Y; Wang Y; Ji QS; Zhu P; Wu BX; Zheng Y; Wang PP; Li J
BMC Cardiovasc Disord; 2016 Oct; 16(1):201. PubMed ID: 27770771
[TBL] [Abstract][Full Text] [Related]
39. [Efficacy and safety of sildenafil therapy in pulmonary artery hypertension: a meta-analysis].
Kuang TG; Wang J; Zhai ZG; Guo XH; Wang C
Zhonghua Yi Xue Za Zhi; 2007 Apr; 87(15):1021-4. PubMed ID: 17672963
[TBL] [Abstract][Full Text] [Related]
40. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
